Cargando…

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis

BACKGROUND: Follicular lymphoma (FL) is considered incurable because remission and relapse are common. Although various salvage treatment options have been proposed, there is no consensus on treatment strategy for FL patients who failed primary treatment. METHODS: This single-center study analyzed p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yong-Pyo, Lee, Min-Sang, Yoon, Sang Eun, Cho, Junhun, Bang, Yeong Hak, Shim, Joon Ho, Kim, Won Seog, Kim, Seok Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529394/ https://www.ncbi.nlm.nih.gov/pubmed/36199784 http://dx.doi.org/10.1155/2022/2263217

Ejemplares similares

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ
por: Koh, Hyun‐Hee, et al.
Publicado: (2023)

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2020)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
por: Kim, Seok Jin, et al.
Publicado: (2023)

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2022)

Metabolic activity of extranodal NK/T cell lymphoma on (18)F-FDG PET/CT according to immune subtyping
por: Lim, Chae Hong, et al.
Publicado: (2021)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
por: Cho, Jang Ho, et al.
Publicado: (2021)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
por: Hur, Joon Young, et al.
Publicado: (2020)

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma
por: Lee, Ji Yun, et al.
Publicado: (2021)

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2023)

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
por: Maeng, Chi Hoon, et al.
Publicado: (2016)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
por: Lee, Hansang, et al.
Publicado: (2019)

Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
por: Kim, Seok Jin, et al.
Publicado: (2018)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

Evaluating waiting time with real-world health information in a high-volume cancer center
por: Kim, Kyu-pyo, et al.
Publicado: (2020)

Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
por: Yoon, Sang Eun, et al.
Publicado: (2020)

PB2281: TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)
por: Damaj, Gandhi Laurent, et al.
Publicado: (2023)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
por: Lim, Chae Hong, et al.
Publicado: (2021)

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Pediatric Follicular Lymphoma: A Rare Variant
por: Lee, Hyun Ji, et al.
Publicado: (2018)

Follicular Lymphoma Patient Relapsing with Paraneoplastic Sensory Neuronopathy (Ganglioneuropathy)
por: Öztürk, Kadir, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p1uf4hb3t4hutj7s0fb4n184l2